Uroplakin IIIa Is a Marker in Bladder Cancer but Seems Not to Reflect Chemical Carcinogenesis

Szymańska, Beata; Matuszewski, M; Dembowski, Janusz; Zdrojowy, Romuald; Długosz, Anna

doi:10.1155/2018/8315410

Cited by 7 publications

(8 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies on UPIIIa in patients with BC showed signi cantly higher levels of UPIIIa in the plasma and urine of patients with bladder cancer compared to controls, but the malignancy and invasiveness of the cancer made no signi cant difference [15].…”

Section: Discussionmentioning

confidence: 71%

See 1 more Smart Citation

Initial Evaluation of Uroplakins UPIIIa and UPII in Selected Benign Urological Diseases

Szymańska

Matuszewski

Dembowski

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundUroplakins (UPs) are glycoproteins that play a specific role in the structure and function of the urothelium. Disorders of normal expression of uroplakins are associated with the pathogenesis of infections and neoplasms of the urinary tract, primary vesicoureteral reflux, hydronephrosis and renal dysfunction. The appearance of uroplakins in the urine and/or plasma may be of potential importance in the detection of urinary tract dysfunction. The aim of the study was to investigate uroplakin IIIa (UPIIIa) and uroplakin II (UPII) expression in patients with selected urological diseases. Plasma and urine from patients with benign prostatic hyperplasia (BPH), urethral stricture (US), urinary tract infection (UTI) and urolithiasis, were compared to healthy people without urological disorders. MethodsA total 152 of human urine and plasma samples from normal and patients with selected benign urological diseases were analyzed. UPs concentration was measured by immunoenzymatic method. All calculations were done using the STATISTICA 13.3 (TIBCO software Inc.).ResultsIn patients with BPH and UTI, UPIIIa in urine and plasma also UPII in urine concentrations were statistically significantly higher than in the control groups. In the US group, only the plasma UPIIIa concentration differed significantly from the control. There were no significant differences between the concentrations of UPs compared to the controls in both the urine and plasma of patients with urolithiasis. ConclusionThe conducted research shows that benign urological diseases may affect the state of the urothelium, as manifested by an increased concentration of both UPs in patients’ urine and plasma, especially in BPH and UTI.

show abstract

Section: Discussionmentioning

confidence: 71%

“…In our previous studies, we assessed the expression of UPIIIa and UPII in the urine and plasma of patients with bladder cancer (BC) [15,16]. We have already conducted studies on the expression of UPIIIa and UPII.…”

Section: Introductionmentioning

confidence: 99%

Initial Evaluation of Uroplakins UPIIIa and UPII in Selected Benign Urological Diseases

Szymańska

Matuszewski

Dembowski

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…No studies reported the roles of UPK3A in HCC until now, but the related research on bladder cancer may indirectly clarify its possible oncogenic functions: UPK3A levels in serum, plasma, and urine were shown to be elevated in patients compared with healthy controls and associated with muscle-invasive status, high grade, lymphovascular invasion, and cancer-specific mortality. [ 52 53 ]…”

Section: Discussionmentioning

confidence: 99%

Integrated analysis identifies a long non-coding RNAs-messenger RNAs signature for prediction of prognosis in hepatitis B virus-hepatocellular carcinoma patients

Bai¹,

Li²,

Li³

et al. 2020

Medicine

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC), but HBV-HCC related prognosis signature remains rarely investigated. This study was to identify an integrated long non-coding RNAs-messenger RNAs (lncRNA-mRNA) signature for prediction of overall survival (OS) and explore their underlying functions. One RNA-sequencing dataset (training set, n = 95) and one microarray dataset E-TABM-36 (validation set, n = 44) were collected. Least absolute shrinkage and selection operator analysis was performed to identify an lncRNA-mRNA prognosis signature. The OS difference of patients in the high-risk and low-risk risk groups was evaluated by Kaplan–Meier curve. Area under the receiver operating characteristic curve (AUC), Harrell concordance index (C-index) calculation, and multivariate analyses with clinical characteristics were used to determine the prognostic ability. Furthermore, a coexpression network was constructed to interpret the functions. Nine signature genes (3 lncRNAs and 6 mRNAs) were selected to generate the risk score model. Patients belonging to the high-risk group showed a significantly shorter survival than those of the low-risk group. The prediction accuracy of the risk score for 5-year OS was 0.936 and 0.905 for the training set and validation set, respectively. Also, this risk score was independent of various clinical variables for the prognosis prediction. Incorporation of the risk score remarkably increased the predictive power of the routine clinical prognostic factors (vascular invasion status, tumor recurrence status) (AUC = 0.942 vs 0.628; C-index = 0.7997 vs 0.6908). Furthermore, LncRNA insulin-like growth factor 2 antisense RNA (IGF2-AS) and long intergenic non-protein coding RNA 342 (LINC00342) were predicted to exert tumor suppression effects by regulating homeobox D1 (HOXD1) and secreted frizzled related protein 5 (SFRP5), respectively; while lncRNA rhophilin Rho GTPase binding protein 1 antisense RNA 1 (RHPN1-AS1) may possess carcinogenic potential by promoting the transcription of chromobox 2 (CBX2), cell division cycle 20 (CDC20), matrix metallopeptidase 12 (MMP12), stratifin (SFN), tripartite motif containing 16 (TRIM16), and uroplakin 3A (UPK3A). These mRNAs may be associated with cell proliferation or apoptosis related pathways. This study may provide a novel, effective prognostic biomarker, and some therapeutic targets for HBV-HCC patients.

show abstract

“…The evaluation of TAC in BC patients urine and measurement of reduced GSH in patients plasma, which was performed to estimate the efficiency of antioxidative processes in patients with ongoing neoplastic process in relationship to changes in UP2 level, were an additional novelty of the study. Moreover, mutual relations between UP2 and other parameters like uroplakin 3a (UP3a), 8-hydroxy-2'deoxyguanosine (8-OHdG), and glutathione S-transferase isozyme- π (GST- π ), which has been previously published, were investigated in the same patients group [15].…”

Section: Introductionmentioning

confidence: 99%

Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer

Matuszewski

Szymańska

Długosz

et al. 2018

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Background Urothelial carcinoma is the most common type of bladder cancer (BC). It makes up more than 90% of all bladder cancers. Uroplakins are tissue-specific, glycoproteins, playing a role in the construction and function of urothelium. The emergence of uroplakins in the urine and/or plasma may be of potential importance in the early detection of BC. In our study, the diagnostic value of plasma and urine uroplakin 2 (UP2) concentration in bladder cancer was investigated, with an assessment of the antioxidant potential of BC patients. The correlation between UP2, total antioxidant capacity (TAC), and concentration of glutathione (GSH) was also examined. Materials and Methods This study included 61 BC patients and 33 healthy controls. UP2 concentration was estimated by the immunoenzymatic method (ELISA). TAC and GSH were determined in spectrophotometrically methods. Results UP2 concentration in BC patients was significantly higher (p≤0.001) both in plasma and in urine compared to the control groups (C). TAC concentration in urine (p≤0.001) and GSH concentration in plasma (p=0.047) were significantly lower in BC group compared to the C group. The high specificity and sensitivity for UPK2 in plasma (76%, 80%, respectively) and urine (88%, 84%, respectively) were observed. Positive correlations were observed between concentration of UP2 in plasma and TAC concentration in urine and between UP2 concentration in plasma and GSH concentration in the same material. Conclusion The study showed the early diagnostic value of urine and plasma UP2 in BC. There was a decrease in UP2 concentration in the urine of patients with the development of BC. The decrease of antioxidant systems (TAC, GSH) indicates their relationship with the BC process. Based on the obtained results, it is justified to continue the study in a larger group of patients with BC.

show abstract

Uroplakin IIIa Is a Marker in Bladder Cancer but Seems Not to Reflect Chemical Carcinogenesis

Cited by 7 publications

References 35 publications

Initial Evaluation of Uroplakins UPIIIa and UPII in Selected Benign Urological Diseases

Initial Evaluation of Uroplakins UPIIIa and UPII in Selected Benign Urological Diseases

Integrated analysis identifies a long non-coding RNAs-messenger RNAs signature for prediction of prognosis in hepatitis B virus-hepatocellular carcinoma patients

Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer

Contact Info

Product

Resources

About